The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
Dec 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
T cell dysfunctions in myelodysplastic syndromes |
Jan 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes |
Apr 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
Jul 2020 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
Oct 2023 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients |
Jun 2019 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study |
May 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |